Certican 0.25 mg (Tablet)

Unit Price: ৳ 125.00 (6 x 10: ৳ 7,500.00)
Strip Price: ৳ 1,250.00

Medicine Details

Category Details
Generic Everolimus
Company Novartis bangladesh ltd
Also available as
Certican 050 mg tablet Certican 075 mg tablet Afinitor 10 mg tablet Afinitor 5 mg tablet

Title

  • Certican Everolimus Tablets

Categories

  • Immunosuppressant
  • Cancer Treatment
  • Organ Rejection Prophylaxis

Description

  • Certican is indicated in advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Advanced HR+ BC)
  • Advanced Neuroendocrine Tumors (NET)
  • Advanced Renal Cell Carcinoma (RCC)
  • Renal Angiomyolipoma With Tuberous Sclerosis Complex (TSC)
  • Subependymal Giant Cell Astrocytoma (SEGA) With Tuberous Sclerosis Complex (TSC)
  • In combination with ciclosporin for microemulsion & corticosteroids for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant
  • In combination with tacrolimus & corticosteroids for the prophylaxis of organ rejection in patients receiving hepatic transplant
  • Prevents allograft rejection by inhibiting the proliferation and clonal expansion of antigen-activated T cells
  • Forms a complex with the cytoplasmic protein FKBP-12, inhibiting the growth factor-stimulated phosphorylation of the p70 S6 kinase, resulting in cell cycle arrest
  • Dosage varies based on the indication, with recommended doses for different conditions
  • Interacts with CYP3A4 inhibitors & inducers, CYP2D6 substrates with narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines
  • Contraindicated in patients with hypersensitivity to the active substance or other rapamycin derivatives
  • Side effects include stomatitis, constipation, infections, asthenia, fatigue, cough, diarrhea, rash, anemia, nausea, anorexia, edema, dyspnea, pyrexia, vomiting, headache, epistaxis, decreased lymphocytes, increased glucose, pneumonitis, pruritus, dry skin, decreased Hgb, menstrual irregularities, dysgeusia, hypertension, hemorrhage, and tachycardia
  • Pregnancy Category D with potential risk to the fetus
  • Not recommended for lactating women
  • Precautions and warnings for increased risk of angioedema, interstitial lung disease/noninfectious pneumonitis, immunosuppressive effects, infections, mouth ulcers and stomatitis, delay in wound healing, renal failure, angioedema and fluid accumulation, metabolic changes, impaired male fertility, hepatic impairment, fetal harm, and use of live vaccines

Dimensions

  • Tablet form

Color Options

  • None

Functions

  • Immunosuppression
  • Anticancer treatment
  • Organ rejection prophylaxis

Materials

  • Active substance: Everolimus
  • Excipients: Not specified

Technical Specifications

  • Proliferation signal inhibitor
  • Immunosuppressive effect by inhibiting T cell proliferation and clonal expansion
  • Inhibits growth factor-stimulated phosphorylation of p70 S6 kinase
  • Forms a complex with cytoplasmic protein FKBP-12
  • Interacts with CYP3A4 inhibitors & inducers, CYP2D6 substrates with narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines

Design Elements

  • Tablet form
  • Packaging design

Usability Features

  • Oral administration
  • Dose adjustment based on indication
  • Interacts with specific medications
  • Contraindication in hypersensitive patients
  • Management of side effects and precautions

Indications

  • Hormone Receptor-Positive, HER2-Negative Breast Cancer
  • Neuroendocrine Tumors
  • Renal Cell Carcinoma
  • Renal Angiomyolipoma With Tuberous Sclerosis Complex
  • Subependymal Giant Cell Astrocytoma
  • Prophylaxis of organ rejection in renal, cardiac, and hepatic transplant

Pharmacology

  • Prevents allograft rejection
  • Inhibits T cell proliferation and clonal expansion
  • Forms complex with FKBP-12
  • Inhibits growth factor-stimulated phosphorylation of p70 S6 kinase
  • Arrests cells at the G1 stage of the cell cycle

Dosage & Administration

  • Initial dosage based on transplant type
  • Different dosage for cancer and renal conditions
  • Administration with or without food
  • Swallowing whole with water
  • Continued treatment until disease progression or unacceptable toxicity

Interaction

  • CYP3A4 inhibitors & inducers
  • CYP2D6 substrates with narrow therapeutic index
  • PgP inhibitors
  • Rifampicin
  • ACE inhibitors
  • Grapefruit juice
  • Live vaccines

Contraindications

  • Hypersensitivity to the active substance or rapamycin derivatives

Side Effects

  • Stomatitis
  • Constipation
  • Infections
  • Asthenia
  • Fatigue
  • Cough
  • Diarrhea
  • Rash
  • Anemia
  • Nausea
  • Anorexia
  • Edema, peripheral
  • Dyspnea
  • Pyrexia
  • Vomiting
  • Headache
  • Epistaxis
  • Decreased lymphocytes
  • Increased glucose
  • Pneumonitis
  • Pruritus
  • Dry skin
  • Decreased Hgb
  • Menstrual irregularities
  • Dysgeusia
  • Hypertension
  • Hemorrhage
  • Tachycardia
  • Congestive heart failure

Pregnancy & Lactation

  • Pregnancy Category D with potential risk to the fetus
  • Not recommended during lactation

Precautions & Warnings

  • Increased risk of angioedema with ACE inhibitors
  • Monitoring for interstitial lung disease/noninfectious pneumonitis
  • Immunosuppressive effects and increased risk of infections
  • Management of mouth ulcers and stomatitis
  • Delay in wound healing and increased wound-related complications
  • Risk of renal failure, angioedema, and fluid accumulation
  • Metabolic changes and hematologic parameter monitoring
  • Potential fetal harm and use of live vaccines

Therapeutic Class

  • Immunosuppressant

Related Brands